Taking what CEO Adam Grossman called "a different spin on intravenous immunoglobulin [IVIG]" while "trying to provide a product that's very targeted, niche-focused, and is going to provide an advantage to a subset" of the patient population, Adma Biologics Inc. reported positive top-line phase III results in primary immune deficiency diseases (PIDD) with lead compound RI-002.